Viral hepatitis A and B in hemodialysed patients.
In 113 hemodialysed patients, 167 hospitalized patients, and 143 outpatients the frequency of HAV and HBV markers were studied by testing HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe, and anti-HAV. The hemodialysis patients in a dialysis-center had significantly more often HBV markers (85.7%) than those maintained on home-dialysis (46.5%). 29.9% of the hospitalized patients and 32.1% of the outpatients had HBV markers. By the anti-HBc test up to 41% of additional HBV infections could be detected.--The prevalence of anti-HAV was very high in all groups. Significant differences between the hemodialysis patients and the control groups existed only in the age groups up to 39 years.--The frequencies of HAV and HBV markers were related to age, duration of dialysis treatment, transfusional frequency, and transaminases. The HBV appeared as the clinically important hepatitis agent in dialysis.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D006437:Hemodialysis, Home / Q000009:adverse effects; D006506:Hepatitis A / Q000635:transmission*; D006509:Hepatitis B / Q000635:transmission*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006511:Hepatitis B Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens